Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
What is the purpose of this trial?
The purpose of this study is to find the best dose, and what affects, good and/or bad, and experimental drug (MPDL3280A) has when used in combination with bevacizumab and with bevacizumab plus FOLFOX chemotherapy to treat subjects with locally advanced or metastatic solid tumors.
- 18 Years and older
- Genentech, Inc.
- Last Updated:
- Study HIC#: